Cancer Therapeutics and Biotherapeutics Market, By Type (Radiation Therapy, Chemotherapy, Biotherapy, Hormone Therapy and Others), By Top Selling Drugs (Avastin, Rituxan, Revlimid, Velcade, Herceptin, Opdivo, and Others), By Application (Breast Cancer, Lung Cancer, Blood Cancer, Prostate Cancer, Cervical Cancer, Melanoma, Head & Neck Cancer, and Others), By End-Users (Hospital, Consumption, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI505623 | Publish Date: March 2024 | No. of Pages: 170

Cancer Therapeutics And Biotherapeutics Market Overview

Cancer Therapeutics and Biotherapeutics Market was valued at US$ 220.7 Billion in 2024 and is projected to grow at a CAGR of 7.9%to reach US$ 441.6 Billion by 2034.Treatment which is used to stop or prevent cancer is called as therapy. Cancer therapy includes chemotherapy which is a special medicine that shrink or kills the cancer cells. Radiation Therapy uses high-energy rays to kill cancer cells. Hormone Therapy blocks the cancer cells from getting the hormones they need to grow. In cancer therapeutics chemotherapy uses drugs which kill cancer cells. In radiation therapy external beam is used. Biotherapeutics in cancer is a type of treatment which uses body’s immune system for killing cancer cells. Biotherapeutics are also used to prevent or slower the tumor growth and to prevent the spread of cancer. The aim of biotherapeutics is to induce immune system to recognize and kill cancer cells. Biological therapies work by making cancer cells easier for immune system to recognize by targeting the cancer cells turning on & off cell signals which help them to elude immune system cells. Drugs called as immune checkpoint inhibitors target specific chemical receptors on cancer cells by blocking the signals in which the cancer cells send to suppress the immune system. Biological therapies also work by inducing immune system to attack cancer cells – chemicals which stimulate immune system cells can injected into body or sample of immune system may be trained in lab for attacking cancer cells before being reintroduced to the body. Hormone therapy is given by different ways like, by orally – it comes in pills, by injection – given in muscle, in arm, hip, thigh, and right under the skin in fatty part of leg, arm, belly, etc., by surgery – the organ is removed that produce hormones, for e.g.: testicles are removed in men and ovaries are removed in women. However, rising incidence of cancer diseases has given positive impact on target market growth

Cancer Therapeutics And Biotherapeutics Market Dynamics

                        Rising prevalence of cancer diseases and rate of urbanization

Rising prevalence of cancer diseases and rate of urbanization has become the major factor in target market growth. Different types of cancer are rising due to poor and unhealthy lifestyle. Breast cancer, lung cancer, liver & kidney cancer, pancreatic cancer are on rise. Urbanization has given rise in consumption of western food, unhealthy diet, unhealthy lifestyle, use of alcohol intake, cigarette smoking, which has become a fashion trend. Cigarette smoking has become the major factor in developing lung cancer. In U.S. around 80% to 90% lung cancer deaths are caused by cigarette smoking. Tobacco has also become the leading cause of lung cancer as it contains more than 7,000 chemicals. Rise in cigarette smoking has given rise in lung cancer. Lung cancer mortality rates has become higher in urban areas than rural areas because of unhealthy lifestyle, rapid industrialization which has given rise in air pollution, personal behavior, increased use of cigarette smoking, and occupational hazards. Urbanization has given rise in air pollution due to industrialization and rising use of vehicles. In 2016, study in European region has determined that about 5% to 7% of lung cancer was observed in people with no smokers and ex-smokers were attributable to higher level of air pollution as expressed by nitrogen dioxide and road bearing heavy traffic. For instance, in June 2016, difference in lung cancer mortality between city and rural areas were observed in Madrid region and the study determined that most urbanized areas of Madrid region were characterized by higher lung cancer mortality rate. Smoking prevalence from 1985 to 2000 was very high in urban areas and thus it was increased with rapid urbanization.          

For instance, in 2016, (NIH), the relationship between cancer incidence and urbanization in Iran were conducted by using Quantile Regression. Data obtained by Ministry of Health & Medical Education and relationship between urbanization and cancer morbidity was investigated by quantile regression and determined that lung cancer, pancreas, prostate, colorectal and breast cancers increasing with rate of urbanization. 95th percentile for lung cancer, 90th percentile was maximum increase rate of breast cancer, 95th percentile was of prostate cancer, 75th percentile was of colorectal cancer, and 10th percentile for pancreas cancer. According to the results, it was determined that there was significant impact of rising urbanization on cancer morbidity due to risk factors like more pollution in urban areas, poor nutrition food, lack of exercise, smoking, alcohol intake, etc. Urbanization has caused unhealthy lifestyle, change in diet, obesity, lack of exercise, pollution, late marriages fewer children, no breast feeding or lesser feeding for less duration, early menarche, late menopause, which has become major contribution in global rise of breast cancer. According to ‘The World Cancer Report 2020’ it was determined that incidence of breast cancer is consistently rising in India due to high socio-economic status and rapid urbanization.

For instance, in 2023, According to data of Government of India it was determined that Jammu & Kashmir has seen a consistent rise in cancer cases with union territory reporting about 51,000 cancer cases in 2019 to 2022. According to study by Sher-e-Kashmir Institute of Medical Sciences (SKIMS) attributed the rising cancer incidence to dietary practices & lifestyle choices and intake of higher salt content foods in Jammu & Kashmir. According to data published by United Nations in 2018, about 55% of the world’s population resided in urban areas, and it is projected that this percentage will increase over the forecast period. However, the growth in cancer diseases and population in urban areas boosts the demand for Cancer Therapeutics and Biotherapeutics market.

Restrains:

As cancer therapies are used in cancer treatment but it has some side-effects which depends on various types of therapies given to an individual. Side-effects depends upon types of hormone therapy which is received to an individual how its body responds to it. Some therapies like hormone therapy used for prostate and breast cancer may cause side-effects like hot flashes, nausea, diarrhea, fatigue, weakened bones, enlarged and tender breast, vaginal dryness, etc. Radiation therapy can causes some side effects like blurry vision, hair loss, change in skin, headache, memory problem, nausea, vomiting, etc. Chemotherapy lowers amount of blood cells that carry oxygen around the body and if RBCs count drops down a patient can develop anemia which causes lack of energy and tiredness. However, side-effects and expensive cost of cancer therapies may restrain the cancer therapeutics and biotherapeutics market growth.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Cancer Therapeutics And Biotherapeutics Market Segmentation

Cancer Therapeutics and Biotherapeutics Market - segmentation

The Cancer Therapeutics and Biotherapeutics market is segmented based on type, top selling drugs, application, end-users and region.

On the basis of Type, the Cancer Therapeutics and Biotherapeutics market is segmented into Radiation Therapy, Chemotherapy, Biotherapy, Hormone Therapy and others. On the basis of Top Selling Drugs, the target market is segmented into Avastin, Rituxan, Revlimid, Velcade, Herceptin, Opdivo, and others. On the basis of Application, the target market is segmented into Breast Cancer, Lung Cancer, Blood Cancer, Prostate Cancer, Cervical Cancer, Melanoma, Head & Neck Cancer, and others. On the basis of End-Users, the target market is segmented into Hospital, Consumption, and others.

Regional Insights:

On region the Cancer Therapeutics and Biotherapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements. Moreover, rising prevalence of cancer diseases such as lung cancer, breast cancer, prostate cancer, robust and well-developed healthcare infrastructure, rising research & development activities, and technological advancement, is anticipated to increase demand for Cancer Therapeutics and Biotherapeutics in the region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Type - Radiation Therapy, Chemotherapy, Biotherapy, Hormone Therapy and others

By Top Selling Drugs  – Avastin, Rituxan, Revlimid, Velcade, Herceptin, Opdivo, and others

By Application – Breast Cancer, Lung Cancer, Blood Cancer, Prostate Cancer, Cervical Cancer, Melanoma, Head & Neck Cancer, and others

By End-Users - Hospital, Consumption, and others

 

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Cancer Therapeutics and Biotherapeutics Market report based on type, top selling drugs, application, end-users and region:

Cancer Therapeutics and Biotherapeutics Market, By Type:

  • Radiation Therapy
  • Chemotherapy
  • Biotherapy
  • Hormone Therapy
  • Others

Cancer Therapeutics and Biotherapeutics Market, By Top Selling Drugs:

  • Avastin
  • Rituxan
  • Revlimid
  • Velcade
  • Herceptin
  • Opdivo
  • Others

Cancer Therapeutics and Biotherapeutics Market, By Application:

  • Breast Cancer
  • Lung Cancer
  • Blood Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Melanoma
  • Head & Neck Cancer
  • Others

Cancer Therapeutics and Biotherapeutics Market, By End-Users:

  • Hospital
  • Consumption
  • Others

Cancer Therapeutics and Biotherapeutics Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Cancer Therapeutics And Biotherapeutics Market Key Players

The key players operating the Cancer Therapeutics and Biotherapeutics Market includes, Johnson & Johnson, Pfizer Inc., Amgen Inc., Eli Lilly and Company, Bristol-Myers Squibb, Hoffman-La Roche AG, Celgene Corporation, Novartis AG, Merck & Co Inc., AbbVie Inc., and others.

Recent Development:

  • In December 2022, Novartis has received the approval from European Commission for ‘Pluvicto’ a first targeted radioligand therapy for treating progressive PSMA-positive metastatic castration-resistant prostate cancer. ‘Pluvicto’ is approved in combination with ADT (androgen deprivation therapy) with or without AR (androgen receptor) pathway inhibition.
  • In November 2022, Pfizer Inc., has announced its investigational cancer immunotherapy ‘Elranatamab’ received a Breakthrough Therapy Designation from US FDA for treating people with refractory or relapsed multiple myeloma. ‘Elranatamab’ is a B-cell maturation antigen CD3 targeted bispecific antibody.
  • In June 2022, Bristol Myers Squibb has announced to acquire Turning Point Therapeutics Inc. This acquisition will bring ‘Reprotrectinib’ best in class, next generation ROS1/NTRK inhibitor in 2023 with differentiated duration of response for patients with ROS1-positive first line NSCLC (Non-Small Cell Lung Cancer) and will become a new standard of care for patients. The acquisition will further broaden Bristol Myers Squibb leading oncology franchise by adding best in class late stage precision oncology asset.

Cancer Therapeutics And Biotherapeutics Market Company Profile

  • Pfizer Inc.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Johnson & Johnson
  • Amgen Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb*
  • Hoffman-La Roche AG
  • Celgene Corporation
  • Novartis AG*
  • Merck & Co Inc.
  • AbbVie Inc.

 “*” marked represents similar segmentation in other categories in the respective section

Cancer Therapeutics And Biotherapeutics Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Top Selling Drugs
      • Market Snippet, By Application
      • Market Snippet, By End-Users
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5.  Market Segmentation, By Type
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
      • Y-o-Y Growth Analysis (%), 2024 – 2034
      • Segment Trends
    • Radiation Therapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Chemotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Biotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Hormone Therapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
  6.  Market Segmentation, By Top Selling Drugs, 2024 – 2034, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
      • Y-o-Y Growth Analysis (%), 2024 – 2034
      • Segment Trends
    • Avastin
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Rituxan
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Revlimid
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Velcade
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Herceptin
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Opdivo
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
  7.  Market Segmentation, By Application, 2024 – 2034, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
      • Y-o-Y Growth Analysis (%), 2024 – 2034
      • Segment Trends
    • Breast Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Lung Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Blood Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Prostate Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Cervical Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Melanoma
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Head & Neck Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
  8.  Market Segmentation, By End-Users, 2024 – 2034, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
      • Y-o-Y Growth Analysis (%), 2024 – 2034
      • Segment Trends
    • Hospital
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Consumption
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
  9. Global Market, By Region, 2024 – 2034, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
      • Y-o-Y Growth Analysis (%), 2024 – 2034
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By End-Users, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By End-Users, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By End-Users, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By End-Users, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Top Selling Drugs, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By End-Users, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 203
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  1. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  2. Company Profiles
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bristol-Myers Squibb
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Hoffman-La Roche AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Celgene Corporation
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The Cancer Therapeutics and Biotherapeutics Market is segmented into type, top selling drugs, application, end-users and region.

Cancer Therapeutics and Biotherapeutics Market is driven by factors like rising prevalence of cancer diseases and rate of urbanization.

By region, the Cancer Therapeutics and Biotherapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements.

The key players operating the Cancer Therapeutics and Biotherapeutics Market includes, Johnson & Johnson, Pfizer Inc., Amgen Inc., Eli Lilly and Company, Bristol-Myers Squibb, Hoffman-La Roche AG, Celgene Corporation, Novartis AG, Merck & Co Inc., AbbVie Inc., and others.